Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing

References

• Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults. Circulation 92,785–789 (1995).
   Google Scholar
• Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic and pathological profiles. JA/V/A 276,199–204 (1996).
   Google Scholar
• •Seminal article demonstrating that hypertrophic cardiomyopathy (HCM) is a common autopsy finding in young athletes who suffer sudden death events.
   Google Scholar
• Priori SG, Allot E, Blomstrom-Lundqvist C etal Task force on sudden cardiac death of the European Society of Cardiology. Eur. Heart 22,1374–1450 (2001).
   PubMed Web of Science ®Google Scholar
• Wigle ED. Cardiomyopathy: the diagnosis of hypertrophic cardiomyopathy. Heart 86, 709–714 (2001).
   PubMed Web of Science ®Google Scholar
• •Well-written description of the approach to clinically diagnosing HCM.
   Google Scholar
• Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology and therapy (1). N. Engl. Med. 316,780-789 (1987).
   Google Scholar
• Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl. J. Med. 336,775–785 (1997).
   PubMed Web of Science ®Google Scholar
• Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAIVIA 287,1308–1320 (2002).
   PubMed Web of Science ®Google Scholar
• •• State-of-the-art clinical review about HCM. Includes overview of epidemiology, diagnosis and treatment approaches.
   Google Scholar
• McKenna WJ, Spirito P, Desnos M, Dubourg 0, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 77,130–132 (1997).
   Google Scholar
• Maron BJ, Estes NAM III, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 107, 2872–2875 (2003).
   PubMed Web of Science ®Google Scholar
• Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part I. Citrulation 104,2113–2116 (2001).
   PubMed Web of Science ®Google Scholar
• •Review of the epidemiology, clinical features, and genetic basis of HCM with discussion of poor prognostic mutations in HCM.
   Google Scholar
• Wigle ED, Rakowski H, Kimball BP eta]. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 92, 1680–1692 (1995).
   PubMed Web of Science ®Google Scholar
• Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 64,437–441 (1981).
   PubMed Web of Science ®Google Scholar
• Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am j Calrliol. 62,1085–1088 (1988).
   Google Scholar
• Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl. J. Med. 307, 997–999 (1982).
   PubMed Web of Science ®Google Scholar
• McKenna W, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification and prevention of sudden death. Heart 87,169–176 (2002).
   PubMed Web of Science ®Google Scholar
• Zipes DR Management of cardiac arrhythmias: pharmacological, electrical and surgical techniques. In: Heart Disease: a Textbook of Cardiovascular Medicine. Braunwald E (Ed.), WB Saunders Company, PA, USA, 593–639 (1997).
   Google Scholar
• Spirito P, Rapezzi C, Bellone P eta]. Infective endocarditis in hypertrophic cardiomyopathy. Circulation 99, 2132–2137 (1999).
   Google Scholar
• MCKully RB, Nishimura RA, Tajik AJ etal Extent of clinical improvement after surgical treatment of hypertrophic cardiomyopathy. Circulation 94, 467–471 (1996).
   PubMedGoogle Scholar
• •The Mayo Clinic experience regarding efficacy and safety of surgical myotomy-myectomy.
   Google Scholar
• Kofflard MJ, van Herwerden LA, Waldstein DJ etal Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. jAm. Coll Calrliol. 28,197–202 (1996).
   PubMed Web of Science ®Google Scholar
• Hassenstein P, Storch H-H, Schmitz W Results of electrical pacing in patients with obstructive cardiomyopathy. Thoraxchirurgie 23,496–498 (1975).
   Google Scholar
• McDonald K, McWilliams E, O'Keefe B et al Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart 9,893–898 (1988).
   PubMed Web of Science ®Google Scholar
• McDonald KM, Maurer B. Permanent pacing as treatment for hypertrophic cardiomyopathy. Am j Canliol 68, 108–110 (1991).
   Google Scholar
• Nishimura RA, Hayes DL, Ilstrup DM et al Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: acute Doppler echocardiographic and catheterization hemodynamic study. Am. Coll. Cardiol 27,421–430 (1996).
   PubMed Web of Science ®Google Scholar
• Maron BJ, Nishimura RA, McKenna W et al Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 99,2927–2933 (1999).
   PubMed Web of Science ®Google Scholar
• Martin WA, Sigwart U. Who and how to treat with non-surgical myocardial reduction therapy in hypertrophic cardiomyopathy: long-term outcomes. Heart Fail Montt 3,15–27 (2002).
   PubMedGoogle Scholar
• Gietzen FH, Launer CJ, Raute-Kreinsen U et al Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur. Hear t 20,1342–1354 (1999).
   Google Scholar
• Lakkis NM, Nagueh SF, Dunn KEA. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. jAm. Coll Canliol 36,852–855 (2000).
   Google Scholar
• Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 97,41–47 (1998).
   Google Scholar
• Masutomo K, Makino N, Fushiki MS. Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters. Mal Cell Biochem. 224,19–27 (2001).
   Google Scholar
• Lim DS, Lutucuta S, Bachireddy P et al Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103,789–791 (2001).
   PubMed Web of Science ®Google Scholar
• Patel R, Nagueh SF, Tsybouleva N et al Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104,317–324 (2001).
   PubMed Web of Science ®Google Scholar
• Marian AJ. Modifier genes for hypertrophic cardiomyopathy. CUI7: Opin. Cardiol 17, 242–252 (2002).
   Google Scholar
• Guidelines AANP. ACC/AHA/NASPE 2002 guidelines update for implantation of cardiac pacemakers and anti-arrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 106,2145–2161 (2002).
   Google Scholar
• Maron BJ, Shen W, Link MS eta]. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl. Med 342,365–373 (2000).
   Google Scholar
• •First data regarding utility and complications of implantable cardioverter-defibrillator treatment in a large group of patients with HCM.
   Google Scholar
• Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. j Mal Cell Canliol 33, 655–670 (2001).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of currentunderstanding of molecular genetics of HCM. Includes discussion of genotype-phenotype correlations and pathogenic models of how sarcomeric gene mutations result in HCM.
   Google Scholar
• Richard P, Charron P, Carrier L eta]. Hypertrophic cardiomyopathy. Distribution of disease genes, spectrum of mutations and implications for molecular diagnosis strategy. Circulation 107, 2227–2232 (2003).
   Google Scholar
• Poetter K, Jiang H, Hassanzadeh S etal Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nature Genet. 13, 63–69 (1996).
   PubMed Web of Science ®Google Scholar
• Ashrafian H, Redwood CS, Blair E, Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Wends Genet. 19,263–268 (2003).
   PubMed Web of Science ®Google Scholar
• Robbins J, Leinwand LA. Structure and function relationship in contractile proteins. In: Molecular Basis of Catrliovascular Disease. Chien KR (Ed.), WB Saunders Company, PA, USA, 191–210 (1999).
   Google Scholar
• Jarcho JA, McKenna W Pare JA et al Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N. Engl. Med. 321,1372-1378 (1989).
   Google Scholar
• Geisterfer-Lowrance AA, Kass S, Tanigawa G et al A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. c1162, 999–1006 (1990).
   Google Scholar
• Watkins H, Thierfelder L, Anan R et al Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy. Am. j Hum. Genet. 53,1180–1185 (1993).
   PubMed Web of Science ®Google Scholar
• Towbin JA, Bowles NE. Molecular diagnosis of myocardial disease. Expert Rev Mol Diagn. 2,587–602 (2002).
   PubMedGoogle Scholar
• Kamisago M, Sharma SD, DePalma SR etal Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. Med. 343,1688–1696 (2000).
   PubMed Web of Science ®Google Scholar
• Niimura H, Bachinski LL, Sangwatanaroj S etal Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N. Engl. Med. 338,1248–1257 (1998).
   PubMed Web of Science ®Google Scholar
• Charron P, Doubourg 0, Desnos M etal. Genotype—phenotype correlations in hypetrophic cardiomyopathy. A comparison between mutations in the cardiac protein C and the beta-myosin heavy chain genes. Eur Heard 19,139–145 (1998).
   Google Scholar
• Carrier L, Bonne G, Bahrend E et al Organization and sequence of human cardiac myosin binding protein-C gene (IVIYBPC3)and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Chr. Res. 80,427-434 (1997).
   Google Scholar
• Niimura H, Patton KIK, McKenna WJ etal Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 105,446–451 (2002).
   PubMed Web of Science ®Google Scholar
• •Study of sporadic cases of HCM that occurred in the elderly and demonstrated mutations in three sarcomeric proteins.
   Google Scholar
• Daehmlow S, Erdmann J, Knueppel T etal Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 298,116–120 (2002).
   PubMed Web of Science ®Google Scholar
• McConnell BK, Jones IKA, Fatkin D etal Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. Clin. Invest. 104,1235–1244 (1999).
   Google Scholar
• Watkins H, McKenna WJ, Thierfelder L etal Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl. Med. 332,1058–1064 (1995).
   PubMed Web of Science ®Google Scholar
• Varnava AM, Elliot P, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy. Histopathological features of sudden death in cardiac troponin T disease. Circulation 104,1380–1384 (2001).
   Google Scholar
• Kimura A, Harada H, Park J-E etal Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Natum Genet. 16,379–382 (1997).
   PubMed Web of Science ®Google Scholar
• Mogensen J, Kubo T, Duque M etal Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. j Clin. Invest. 111, 209–216 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ, Gessner R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum. Mutat. 17,524 (2001).
   Google Scholar
• Olson TM, Karst ML, Whitby FG, Driscoll DJ. Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. Circulation 105, 2337–2340 (2002).
   PubMed Web of Science ®Google Scholar
• Miyata S, Minobe W Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Cur. Res. 86,386–390 (2000).
   Google Scholar
• Thierfelder L, Watkins H, MacRae C etal Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Ce1177, 701–712 (1994).
   Google Scholar
• Coviello DA, Maron BJ, Spirito P etal Clinical features of hypertrophic cardiomyopathy caused by mutation of a 'hot spot' in the alpha-tropomyosin gene. Am. Coll Cardiol 29,635–640 (1997).
   PubMed Web of Science ®Google Scholar
• Karibe A, Tobacman LS, Strand J eta]. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling and poor prognosis. Circulation 103,65–71 (2001).
   Google Scholar
• Jongbloed RJ, Marcelis CL, Doevendans PA etal Variable clinical manifestation of a novel missense mutation in the alpha-tropomyosin (7PM1)gene in familial hypertrophic cardiomyopathy. Am. Coll Cardiol 41,981–986 (2003).
   Google Scholar
• Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280,750–752 (1998).
   Google Scholar
• Mogensen J, Klausen IC, Pedersen AK etal Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. Clin. Invest. 103, R39—R43 (1999).
   Google Scholar
• Olson TM, Doan TP, Kishimoto NY etal Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. j Mal Cell. Camliol 32, 1687–1694 (2000).
   PubMed Web of Science ®Google Scholar
• Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem. Biophys. Res. Commun. 262,411–417 (1999).
   PubMed Web of Science ®Google Scholar
• Gerull B, Gramlich M, Atherton J etal Mutations of TIN encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nature Genet. 30, 201–204 (2002).
   PubMed Web of Science ®Google Scholar
• Itoh-Satoh M, Hayashi T, Nishi H etal Titin mutations as the molecular basis of dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 291,385–391 (2002).
   PubMed Web of Science ®Google Scholar
• Watkins H. Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management. Eur Heard 3, L43—L50 (2001).
   Google Scholar
• Gollob MET, Green MS, Tang AS etal Identification of a gene responsible for familial Wolff—Parkinson—White syndrome. N. Engl. Med 344,1823–1831 (2001).
   PubMed Web of Science ®Google Scholar
• Blair E, Redwood C, Ashrafian H etal Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mal Genet. 10, 1215–1220 (2001).
   Google Scholar
• Arad M, Benson DW, Perez-Atayde AR etal Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. Clin. Invest. 109,357–362 (2002).
   Google Scholar
• Arad M, Moskowitz IP, Patel VV etal Transgenic mice overexpressing mutant PRK4G2 define the cause of Wolff—Parkinson—White syndrome in glycogen storage cardiomyopathy. Circulation 107,2850–2856 (2003).
   PubMed Web of Science ®Google Scholar
• Geier C, Perrot A, Ozcelik C eta]. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 107, 1390–1395 (2003).
   Google Scholar
• Williams RS. Canaries in the coal mine: mitochondrial DNA and vascular injury from reactive oxygen species. Cur. Res. 86, 915–916 (2000).
   Google Scholar
• Hirano M, Davidson M, DiMauro S. Mitochondria and the heart. Curl: Opin. Cardiol 16,201–210 (2001).
   Google Scholar
• Taylor RW, Giordano C, Davidson MM etal A homoplasmic mitochondrial transfer acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy. film. Coll Camliol 41,1786–1796 (2003).
   PubMed Web of Science ®Google Scholar
• Palau E Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis. Int. j Mal Med 7,581–589 (2001).
   Google Scholar
• Korade-Mimics Z, Babitzke P, Hoffman E. Myotonic dystrophy: molecular windows on a complex etiology. Nucleic Acids Res. 26, 1363–1368 (1998).
   PubMed Web of Science ®Google Scholar
• Linhart A, Magage S, Palecek T etal Cardiac involvement in Fabry disease. Acta Paediatr Suppl 439,15–20 (2002).
   Google Scholar
• •Detailed overview of cardiac involvement in Fabry disease.
   Google Scholar
• Schiffmann R, Kopp JB, Austin HA etal Enzyme replacement therapy in Fabry disease. PIN/A 285,2743–2749 (2001).
   Google Scholar
• Perrot A, Osterziel KJ, Beck M etal Fabry disease: focus on cardiac manifestations and molecular mechanisms. Herz27, 699–702 (2002).
   PubMed Web of Science ®Google Scholar
• Sachdev B, Takenaka T, Teraguchi H etal Prevalence of Anderson—Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105, 1407–1411 (2002).
   PubMed Web of Science ®Google Scholar
• Eng CM, Guffon N, Wilcox WR etal Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry disease. N Eng. Merl 345,9–16 (2001).
   PubMed Web of Science ®Google Scholar
• •The first randomized, placebo-controlled, double-blind study to test safety and efficacy of a-galactosidase in the treatment of Fabry disease.
   Google Scholar
• Desnick RJ, Brady R, Barranger J etal Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management and enzyme replacement therapy. Ann. Intern. Merl 138,338–346 (2003).
   PubMed Web of Science ®Google Scholar
• Denfield SW, Towbin JA. Hypertrophic cardiomyopathy and its management in children. ACC Cun j Rev 4,40–42 (1995).
   Google Scholar
• Frey N, Olson EN. Making matters worse for a broken heart. j Clin. Invest. 106, 1437–1439 (2000).
   PubMed Web of Science ®Google Scholar
• Cuda G, Fananapazir L, Zhu WS, Sellers JR, Epstein ND. Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. Clin. Invest. 91,2861–2865 (1993).
   Google Scholar
• Maass A, Leinwand LA. Animal models of hypertrophic cardiomyopathy. CU17: Opin. Camliol 15,189–196 (2000).
   Google Scholar
• Vikstrom KL, Facxtor SM, Leinwand LA. Mice expressing mutant myosin heavy chains are model for familial hypertrophic cardiomyopathy. Mot. Merl Today 2, 556–567 (1996).
   Google Scholar
• Fatkin D, Christe ME, Aristizabal 0 eta]. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutant in the CL-cardiac myosin heavy chain gene. Clin. Invest. 103,147-153 (1999).
   Google Scholar
• Marian AJ, Wu Y, Lim D-S etal. A transgenic rabbit model for human hypertrophic cardiomyopathy. j Clin. Invest. 104,1683–1692 (1999).
   Google Scholar
• Arber S, Hunter JJ, Ross JJ et al MLP-deficient mouse exhibits a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy and heart failure. c1188, 393–403 (1997).
   Google Scholar
• Moolman JC, Corfield VA, Posen B et al Sudden death due to troponin T mutations. jAm. Coll. Canliol 29, 549–555 (1997). Websites
   Google Scholar